Search

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
Testing three column cards
Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022
Community Bulletin: Intent to Submit an Accelerated Approval Biologics License Application for SRP-9001
Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer